COVID-19疫苗制造商BioNTech宣布关闭位于德国马尔堡、伊达尔-奥伯施泰因和图宾根的三个生产基地，同时停止新加坡的运营1。这一决定源于该公司寻找这些设施买家的努力失败1。此次关闭预计将影响约1800名员工1。
BioNTech表示，此举是应对COVID-19疫苗需求大幅下降导致的产能过剩问题1。公司在声明中指出，"由于市场和投资环境困难，寻找买家的努力未取得成功"1。这次关闭措施是该公司5月宣布的制造业务重组计划的一部分1。根据预期，重组完成后公司年度可节省约5亿欧元1。为妥善安置受影响员工，BioNTech已与工作委员会就员工遣散费条款达成协议1。
BioNTech, the German biotechnology company behind a major COVID-19 vaccine, announced the closure of manufacturing facilities in Marburg, Idar-Oberstein, and Tübingen, as well as its operations in Singapore.1 The decision follows unsuccessful efforts to find buyers for these sites, according to the company's statement that cited "difficult market and investment conditions."1
The restructuring will affect approximately 1,800 employees across the affected locations.1 This closure is part of a broader manufacturing reorganization plan announced in May 2026 to address overcapacity resulting from sharply declining demand for COVID-19 vaccines.1 The company has reached an agreement with works councils regarding additional severance terms for affected workers.1 BioNTech expects the consolidation to generate annual savings of approximately 500 million euros (587 million dollars).1
评论
还没有评论，欢迎留下第一条。